MannKind Corp (NASDAQ:MNKD) — Market Cap & Net Worth
Market Cap & Net Worth: MannKind Corp (MNKD)
MannKind Corp (NASDAQ:MNKD) has a market capitalization of $1.14 Billion ($1.14 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8298 globally and #2430 in its home market, demonstrating a -12.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MannKind Corp's stock price $3.56 by its total outstanding shares 321544484 (321.54 Million). Also see MNKD current and non-current assets for a full breakdown of the balance sheet.
MannKind Corp Market Cap History: 2015 to 2026
MannKind Corp's market capitalization history from 2015 to 2026. Data shows change from $2.33 Billion to $1.14 Billion (-13.27% CAGR). Also see MNKD operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
MannKind Corp is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 0.10% | #23 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #240 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #902 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.06% | #140 of 263 |
Weight: MannKind Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MannKind Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MannKind Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for MannKind Corp for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.22x
MannKind Corp's market cap is 5.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
310.96x
MannKind Corp's market cap is 310.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.02 Billion | $174.76 Million | $125.66 Million | 5.86x | 8.15x |
| 2017 | $745.98 Million | $11.74 Million | -$117.33 Million | 63.51x | N/A |
| 2018 | $340.84 Million | $27.86 Million | -$86.97 Million | 12.23x | N/A |
| 2019 | $414.79 Million | $63.04 Million | -$51.90 Million | 6.58x | N/A |
| 2020 | $1.01 Billion | $65.14 Million | -$57.24 Million | 15.45x | N/A |
| 2021 | $1.41 Billion | $75.44 Million | -$80.93 Million | 18.63x | N/A |
| 2022 | $1.69 Billion | $99.77 Million | -$87.40 Million | 16.98x | N/A |
| 2023 | $1.17 Billion | $198.96 Million | -$11.94 Million | 5.88x | N/A |
| 2024 | $2.07 Billion | $285.50 Million | $27.59 Million | 7.24x | 74.94x |
| 2025 | $1.82 Billion | $348.97 Million | $5.86 Million | 5.22x | 310.96x |
Competitor Companies of MNKD by Market Capitalization
Companies near MannKind Corp in the global market cap rankings as of September 16, 2026. Review MannKind Corp tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to MannKind Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
MannKind Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, MannKind Corp's market cap moved from $2.33 Billion to $ 1.14 Billion, with a yearly change of -13.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.14 Billion | -37.21% |
| 2025 | $1.82 Billion | -11.82% |
| 2024 | $2.07 Billion | +76.65% |
| 2023 | $1.17 Billion | -30.93% |
| 2022 | $1.69 Billion | +20.59% |
| 2021 | $1.41 Billion | +39.62% |
| 2020 | $1.01 Billion | +142.64% |
| 2019 | $414.79 Million | +21.70% |
| 2018 | $340.84 Million | -54.31% |
| 2017 | $745.98 Million | -27.12% |
| 2016 | $1.02 Billion | -56.09% |
| 2015 | $2.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of MannKind Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more